Inmazeb: new hope for Zaire Ebola virus disease
Keywords:Ebola virus, Inmazeb, Atoltivimab, Maftivimab, Odesivimab
Ebola virus disease first appeared in 1976 in Zaire (now democratic republic of Congo). Since then virus outbreaks occurred periodically in African countries. The cases notified in March 2014 in west Africa was largest outbreak till now. In 2020 there is ongoing outbreak of Zaire Ebola virus in democratic republic of Congo. Ebola virus is single stranded RNA virus which causes viral hemorrhagic fever in humans presenting as high fever, chills, loss of appetite, myalgia, headache. Till now there was no specific treatment, symptomatic treatment methods including infusion of electrolyte and/or antibiotics were mainly used. In October 2020 FDA approved the first treatment for Zaire Ebola virus disease in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection. The treatment is called Inmazeb, combination of three recombinant human IgG1κ monoclonal antibodies (Atoltivimab, Maftivimab, and Odesivimab-ebgn) each targeting the Zaire ebolavirus glycoprotein.
Burke J, Ghysebrechts SG, Pattyn SR, Piot P, Ruppol JF, Thonon D et al. Ebola hemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56(2):271-93.
Feldman H, Sanchez A, Geisbert WT. Filoviridae: Marburg and Ebolaviruses. In: Knipe DM, Howley PM, editors. Fields in virology. Philadelphia: Lippincott Willams and Wilkins. 2013;923-56.
Chowell G, Nishiura H. Transmission dynamics and control of Ebola virus disease (EVD): a review. BMC Med. 2014;12(1):196.
World Health Organization. Fact sheet: ebolavirus disease. Available at: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease. Accessed on 7 November 2020.
Mehedi M, Groseth A, Feldmann H, Ebihara H. Clinical aspects of Marburg hemorrhagic fever. Future Virol. 2011;6(9):1091-06.
UCSC Genome Informatics Group. UCSC Ebola genome portal. Available at: https://genome.ucsc.edu/ebolaPortal/. Accessed on November 19, 2020.
Maganga GD, Kapetshi J, Berthet N, KebelaIlunga B, Kabange F, Mbala Kingebeni P et al. Ebola virus disease in the Democratic Republic of Congo. N Engl J Med. 2014;371(22):2083-91.
Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155:2083-103.
Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438(7068):575-6.
Feldmann H, Geisbert TW. Ebola hemorrhagic fever. Lancet. 2011;377(9768):849-62.
Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT. Ebola virus outbreaks in Africa: past and present. Onderstepoort J Vet Res. 2012;79(2):451.
Sandra LB, Allen J, Sina B. Discovering Drugs for the Treatment of Ebola Virus. Curr Treatment Options Infect Dis. 2017;9(3):299-317.
Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK et al. Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402-9.
U. S. Food and Drug Administration. press announcements. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus. Accessed on 7 November 2020.
Regeneron’s Inmazeb becomes the first FDA-approved treatment for Ebola. Available at: https://www.biopharma-reporter.com/Article/2020/10/15/Regeneron-s-Inmazeb-becomes-first-FDA-approved-Ebola-treatment. Accessed on 12 November 2020.
U.S. Food and Drug Administration. Drugs label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761169s000lbl.pdf. Accessed on 12 November 2020.